(Q36371542)

13 August 2017

1 reference

title

Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease (English)

1 reference

13 August 2017

Replacement Therapy with Virus-Inactivated Plasma Concentrates in von Willebrand Disease (English)

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

blood component transfusion

20 October 2022

main subject

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1642002

20 October 2022

author

Pier Mannuccio Mannucci

4

object named as

Mannucci PM

1 reference

13 August 2017

F. Rodeghiero

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1642002

20 October 2022

G. Castaman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1642002

20 October 2022

D. Meyer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1642002

20 October 2022

language of work or name

1 reference

1 January 1992

1 reference

full work available at URL

13 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1423-0410.1992.tb01198.x

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1423-0410.1992.tb01198.x/fullpdf

20 October 2022

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

20 October 2022

1 reference

13 August 2017

volume

62

1 reference

13 August 2017

issue

4

1 reference

13 August 2017

page(s)

193-199

1 reference

Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1992.TB01198.X

Pool's cryoprecipitate and exhausted plasma in the treatment of von Willebrand's disease and factor-XI deficiency

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

The treatment of haemorrhage in von Willebrand's disease and the blood level of factor VIII (AHG)

20 October 2022

5

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Congenital bleeding disorders with long bleeding time and normal platelet count. II. Von Willebrand's disease (report of thirty-seven patients)

20 October 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

High potency factor VIII concentrate: More effective than cryoprecipitate in a patient with Von Willebrand's disease and inhibitor

20 October 2022

8

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates

20 October 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Failure of AHF concentrate to control bleeding in von Willebrand's disease

20 October 2022

11

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities

20 October 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease

20 October 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Von Willebrand's disease and its correction with human plasma fraction 1-0

20 October 2022

16

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag System

20 October 2022

18

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor

20 October 2022

19

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Studies on the prolonged bleeding time in von Willebrand's disease

20 October 2022

20

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Virucidal treatment of clotting factor concentrates

20 October 2022

23

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates

20 October 2022

24

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates

20 October 2022

25

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Characteristics of Various Factor VIII Concentrates used in Treatment of Haemophilia A

20 October 2022

26

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates

20 October 2022

27

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Transfusion Studies in von Willebrand's Disease: Effect on Bleeding Time and Factor VIII

20 October 2022

30

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease

20 October 2022

31

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

The use of heat-treated Factor VIII-concentrates in von Willebrand's disease

20 October 2022

34

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

In vitro and in vivo characterization of a high-purity, solvent/detergent-treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's disease

20 October 2022

35

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y)

20 October 2022

37

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand's disease

20 October 2022

38

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Platelet function and immunologic parameters in von Willebrand's disease following cryoprecipitate and factor VIII concentrate infusion

20 October 2022

39

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

Transfusion and Gel Filtration Studies in von Willebrand's Disease

20 October 2022

43

1 reference

https://api.crossref.org/works/10.1111/J.1423-0410.1992.TB01198.X

20 October 2022

Identifiers

1 reference

13 August 2017

1 reference